Table 1.

Real-time effects of immunosuppressants on relative high-energy phosphate concentrations in perfused rat brain slices calculated from ex vivo ³¹P-MRS: (A) phosphocreatine/PME changes; (B) ATP/PME changes; (C) NAD⁺/PME changes

	CsA (%)	SRL (%)	RAD (%)	CsA+SRL (%)	CsA+RAD (%)
(A) PCr
2 h	84±5*	87±6*	95±10	64±12**	101±8
4 h	69±9**	85±4*	102±6	60±7**	102±12
6 h	87±10	82±7*	97±12	62±12**	97±2
8 h	97±12	83±9*	90±7	57±10**	99±7
10 h	95±9	81±9*	99±3	54±20**	94±12
(B) ATP
2 h	84±2*	90±5	104±6	69±11**	97±4
4 h	75±9*	89±7	112±9	64±9**	91±7
6 h	85±7*	85±3*	107±6	65±7**	93±12
8 h	88±10	80±4**	115±5*	60±12**	109±8
10 h	89±4	80±7*	109±7	58±8***	104±10
(C) NAD+
2 h	57±9*	102±7	125±12*	62±12**	111±4*
4 h	48±25*	98±7	125±11*	71±12*	135±18*
6 h	59±14*	95±12	127±24	61±17*	103±8
8 h	62±12**	100±14	113±3*	50±8***	89±12
10 h	74±14**	102±8	127±9*	38±7***	94±7

Results are given as percent from baseline (mean±s.d., n=4). Significance levels: ^*P<0.05;

^**P<0.01;

^***P<0.001.

Rat brain slices were perfused with 500 μg l⁻¹ cyclosporine, 100 μg l⁻¹ sirolimus, 100 μg l⁻¹ everolimus, or their combinations.

CsA, cyclosporine; NAD⁺, nicotinamide adenine dinucleotide; PCr, phosphocreatine; PME, phosphomonoesters; RAD, everolimus; SRL, sirolimus.